Brief: Lantern Pharma Reports Complete Response In Heavily Pre-Treated Lymphoma Patient In Phase 1 Clinical Trial
23/07/2025 13:05
July 23 (Reuters) - Lantern Pharma Inc LTRN.O: LANTERN PHARMA REPORTS COMPLETE RESPONSE IN HEAVILY PRE-TREATED LYMPHOMA PATIENT WITH LP-284 IN PHASE 1 CLINICAL TRIAL Source text: ID:nBw4G23GLa Further company coverage: LTRN.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lantern Pharma
See all newsBrief: Lantern Pharma Receives Taiwan Approvals To Open Next Stage Of Phase 2 Harmonic Trial Of Lp-300 In Never-Smoker, Egfr-Mutant Nsclc
Brief: Lantern Pharma Reports Second Quarter 2026 Financial Results And Provides Business Update
Lantern Pharma Inc reports results for the quarter ended June 30 - Earnings Summary
Lantern Pharma Q2 operating loss widens on warrant expenses tied to higher stock price
Lantern Pharma Inc expected to post a loss of 38 cents a share - Earnings Preview